ISOFOL Isofol Medical AB (publ)
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Isofol Medical (STO: ISOFOL)
›
Isofol Medical (STO: ISOFOL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 0.9900 SEK on 20 November 2026, up 46.9% over 52 weeks. Its 52-week range is 0.5515 SEK to 1.680 SEK: the price is 41.1% below the high and 79.5% above the low.
Its market capitalisation is 317.29M SEK.
Isofol Medical reports return on equity of -50.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 98.09M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 3.625 SEK is 266.2% above the current price.